Physician profile
Dawn K Walker
NPI 1306895529
$2,150.49
in general payments reported to CMS, 2019-2025
28 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $401 · 2021: $319 · 2022: $187 · 2023: $382 · 2024: $472 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $356.92 | 2021-2024 | |
| Novo Nordisk INC | $339.22 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $250.18 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $195.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $181.54 | 2020-2025 | Farxiga |
| Astellas Pharma US INC | $170.57 | 2019-2024 | Myrbetriq, Veozah |
| Lilly USA, LLC | $121.73 | 2019-2022 | |
| Radius Health, INC. | $61.39 | 2019-2020 | |
| Viatris Specialty LLC | $45.51 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.96 | 2024-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $40.77 | 2021-2022 | |
| Dexcom, INC. | $39.50 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $34.74 | 2021-2022 | |
| Allergan, INC. | $28.74 | 2020 | |
| Sanofi-Aventis U.S. LLC | $28.54 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.69 | 2019-2020 | |
| Abbvie INC. | $22.68 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.49 | 2024 | Voquezna |
| Exeltis, USA INC. | $17.14 | 2023 | Slynd |
| Idorsia Pharmaceuticals US INC | $16.56 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $15.65 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.12 | 2019 | |
| Glaxosmithkline, LLC. | $13.79 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.78 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.32 | 2019 | |
| Insulet Corporation | $13.28 | 2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $11.68 | 2019 | |
| Endogastric Solutions, INC | $11.00 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.